MENLO PARK, Calif.--(BUSINESS WIRE)--Dec. 7, 2017--
Intersect ENT, Inc. (Nasdaq: XENT),
today announced that management will present an overview of the
company's business at the 36th Annual J.P. Morgan Healthcare
Conference on Tuesday, January 9, 2018 at 2:30 p.m. PT at the Westin St.
A live webcast of the presentation will be available online from the
Investor Relations page of the Company's website at http://www.intersectENT.com.
The webcast replay will be available for approximately one month.
About Intersect ENT®
Intersect ENT is dedicated to transforming the landscape of care for
patients with ear, nose and throat conditions. The company’s PROPEL®
family of dissolvable steroid releasing sinus implants are clinically
proven to improve outcomes for chronic sinusitis patients undergoing
sinus surgery. In addition, Intersect ENT is continuing to expand its
portfolio of products based on the company’s unique localized steroid
releasing technology and is committed to broadening patient access to
less invasive and more cost effective care.
For additional information on the company or the products including
risks and benefits please visit www.IntersectENT.com.
Intersect ENT® and PROPEL® are registered
trademarks and SINUVA is a trademark of Intersect ENT, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171207006075/en/
Source: Intersect ENT, Inc.
Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105